Changxin Zhong
Changsha, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Targeted Degradation of eEF2K by a Structure-Guided PROTAC Strategy for the Treatment of Triple-Negative Breast Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 22, 2025
Serine/Threonine Kinase 33 as a Novel Target of Bufalin in Treatment of Triple-Negative Breast Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 07, 2025
Identification of a Novel Substrate for eEF2K and the AURKA-SOX8 as the Related Pathway in TNBC.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 15, 2024
GPX4-AUTAC induces ferroptosis in breast cancer by promoting the selective autophagic degradation of GPX4 mediated by TRAF6-p62.
Journal: Cell death and differentiation
Published: October 08, 2024
Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha.
Journal: Nature communications
Published: October 01, 2024
Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2H,4H)-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer.
Journal: Journal of medicinal chemistry
Published: August 29, 2024
Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple-Negative Breast Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: July 23, 2023
Targeting lncRNA DDIT4-AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: December 07, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026